Cowen’s 42nd Annual Health Care Conference

The 43rd Annual Cowen Health Care Conference with a presentation on March 7, 2023, at 10:30 a.m. ET.

Raymond James 2023 Institutional Investors Conference

The 44th Annual Raymond James & Associates Institutional Investors Conference with a presentation on March 6, 2023, at 11:35 a.m. ET.

Events & Presentations

  • 03/07/2023

    Cowen Health Care Conference

  • 03/06/2023

    Raymond James 2023 Institutional Investors Conference

  • 02/28/2023

    Myriad Genetics Fourth Quarter 2022 Financial Earnings

Latest News

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

March 2, 2023

Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry SALT LAKE CITY, M...

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

March 1, 2023

  SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today anno...

Myriad Genetics Reports Fourth Quarter Financial Results

February 28, 2023

Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes Highli...

Stock Information

NASDAQ: MYGN

$23.72

0.09 (0.38)

03/24/2023

DAY HIGH

$23.75

YEAR HIGH

$28.18

DAY LOW

$23.105

YEAR LOW

$13.92

Financial Reports and Filings

  • 03/23/2023 4

    Statement of changes in beneficial ownership of securities
  • 03/23/2023 4

    Statement of changes in beneficial ownership of securities
  • 03/23/2023 4

    Statement of changes in beneficial ownership of securities

Our ESG Story

“For more than 31 years, Myriad Genetics has worked to be a force for good in the world as we fulfill our mission to advance health and well-being for all. In our inaugural ESG report, we seek to convey our core values as a caring, ethical, and sustainable company committed to continuous improvement,” said Paul J. Diaz, president and CEO, Myriad Genetics. “I want to thank our 2,400 teammates for the progress we have made to date, recognizing we have more work to be done. We are committed to intensifying our ESG focus helping to address the needs of the patients, healthcare providers, stakeholders, and communities we serve.”

Screen Shot 2022-08-01 at 2.32.33 PM